Market implies 5.16% perpetual growth yet pays 70.52x earnings for a biotech with 227% R&D-to-OCF ratio.

Alnylam's remarkable profitability inflection from -$405M to +$186M quarterly earnings has created a classic expectations trap where the market prices 5.16% perpetual growth into a 70.52x PE multiple despite 65.2% trailing growth.

What growth does the price imply versus what the business delivers?

This framework suggests the market has created an unusual expectations paradox - pricing conservative long-term growth of 5.16% into an extreme multiple of 70.52x. The gap between implied growth and actual performance indicates the market expects dramatic deceleration despite the profitability inflection.

Is the company creating or destroying value with its capital?

Applying this lens reveals extreme capital intensity where R&D consistently exceeds operating cash flow even in profitable quarters. While high gross margins suggest value creation potential, the reinvestment rate indicates returns on incremental capital remain uncertain.

How long can above-average returns persist?

This framework identifies high concentration risk with two products representing the entire revenue base. While 75%+ gross margins indicate pricing power in specialized therapeutics, the narrow product portfolio suggests a shorter competitive advantage period than the valuation implies.

Is performance driven by sustainable skill or temporary conditions?

Through this lens, the extreme quarterly volatility suggests luck plays a larger role than the consistent revenue beats would indicate. The asymmetric market reactions to surprises reveal investor uncertainty about separating skill from biotech development timing.

Applying the Mauboussin framework reveals a company where exceptional operational progress has created its own valuation trap. The 70.52x PE multiple prices expectations that contradict the conservative 5.16% implied growth rate, while extreme earnings volatility and product concentration challenge the sustainability of current returns. This framework suggests the market has shifted from systematically underestimating Alnylam to potentially overestimating its ability to maintain above-average returns. At what multiple does a biotech miracle become fairly priced?

This analysis applies Michael Mauboussin's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Michael Mauboussin. Educational purposes only. Not financial advice.